Alleviation of cancer anorexia and cachexia: Studies of the mayo clinic and the North Central Cancer Treatment Group

Charles Lawrence Loprinzi, Neil M. Ellison, Richard M. Goldberg, John C. Michalak, Patrick A. Burch

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Anorexia and cachexia are common clinical problems of many patients with advanced cancer. Approximately 20 years ago, a controlled, clinical study demonstrated that dexamethasone could stimulate appetites of patients with advanced gastrointestinal cancer without causing any apparent effect on patient weight or survival. More recently, two double-blind, placebo-controlled trials investigated cyproheptadine and megestrol acetate in patients with cancer anorexia/cachexia. The first of these studies suggested that cyproheptadine could mildly stimulate appetite without causing any discernible effect on patient weight. Megestrol acetate, on the other hand, can clearly cause an increase in patient-perceived appetite and food intake and can also lead to substantial nonfluid weight gain in a proportion of patients with cancer anorexia/cachexia. Ongoing studies have been designed to better study the appetite-enhancing effects of megestrol acetate. In addition, current studies are evaluating the effect of the drug hydrazine sulfate on the appetite and weight status of patients with advanced lung or colon cancer.

Original languageEnglish (US)
Pages (from-to)8-12
Number of pages5
JournalSeminars in Oncology
Volume17
Issue number6 SUPPL. 9
StatePublished - 1990

Fingerprint

Cachexia
Anorexia
Appetite
Megestrol Acetate
Neoplasms
Cyproheptadine
hydrazine
Therapeutics
Weights and Measures
Gastrointestinal Neoplasms
Colonic Neoplasms
Dexamethasone
Weight Gain
Lung Neoplasms
Eating
Placebos
Survival

ASJC Scopus subject areas

  • Oncology

Cite this

Loprinzi, C. L., Ellison, N. M., Goldberg, R. M., Michalak, J. C., & Burch, P. A. (1990). Alleviation of cancer anorexia and cachexia: Studies of the mayo clinic and the North Central Cancer Treatment Group. Seminars in Oncology, 17(6 SUPPL. 9), 8-12.

Alleviation of cancer anorexia and cachexia : Studies of the mayo clinic and the North Central Cancer Treatment Group. / Loprinzi, Charles Lawrence; Ellison, Neil M.; Goldberg, Richard M.; Michalak, John C.; Burch, Patrick A.

In: Seminars in Oncology, Vol. 17, No. 6 SUPPL. 9, 1990, p. 8-12.

Research output: Contribution to journalArticle

Loprinzi, CL, Ellison, NM, Goldberg, RM, Michalak, JC & Burch, PA 1990, 'Alleviation of cancer anorexia and cachexia: Studies of the mayo clinic and the North Central Cancer Treatment Group', Seminars in Oncology, vol. 17, no. 6 SUPPL. 9, pp. 8-12.
Loprinzi, Charles Lawrence ; Ellison, Neil M. ; Goldberg, Richard M. ; Michalak, John C. ; Burch, Patrick A. / Alleviation of cancer anorexia and cachexia : Studies of the mayo clinic and the North Central Cancer Treatment Group. In: Seminars in Oncology. 1990 ; Vol. 17, No. 6 SUPPL. 9. pp. 8-12.
@article{fa7bd5c21ef4478aa2b8d9681433274c,
title = "Alleviation of cancer anorexia and cachexia: Studies of the mayo clinic and the North Central Cancer Treatment Group",
abstract = "Anorexia and cachexia are common clinical problems of many patients with advanced cancer. Approximately 20 years ago, a controlled, clinical study demonstrated that dexamethasone could stimulate appetites of patients with advanced gastrointestinal cancer without causing any apparent effect on patient weight or survival. More recently, two double-blind, placebo-controlled trials investigated cyproheptadine and megestrol acetate in patients with cancer anorexia/cachexia. The first of these studies suggested that cyproheptadine could mildly stimulate appetite without causing any discernible effect on patient weight. Megestrol acetate, on the other hand, can clearly cause an increase in patient-perceived appetite and food intake and can also lead to substantial nonfluid weight gain in a proportion of patients with cancer anorexia/cachexia. Ongoing studies have been designed to better study the appetite-enhancing effects of megestrol acetate. In addition, current studies are evaluating the effect of the drug hydrazine sulfate on the appetite and weight status of patients with advanced lung or colon cancer.",
author = "Loprinzi, {Charles Lawrence} and Ellison, {Neil M.} and Goldberg, {Richard M.} and Michalak, {John C.} and Burch, {Patrick A.}",
year = "1990",
language = "English (US)",
volume = "17",
pages = "8--12",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "6 SUPPL. 9",

}

TY - JOUR

T1 - Alleviation of cancer anorexia and cachexia

T2 - Studies of the mayo clinic and the North Central Cancer Treatment Group

AU - Loprinzi, Charles Lawrence

AU - Ellison, Neil M.

AU - Goldberg, Richard M.

AU - Michalak, John C.

AU - Burch, Patrick A.

PY - 1990

Y1 - 1990

N2 - Anorexia and cachexia are common clinical problems of many patients with advanced cancer. Approximately 20 years ago, a controlled, clinical study demonstrated that dexamethasone could stimulate appetites of patients with advanced gastrointestinal cancer without causing any apparent effect on patient weight or survival. More recently, two double-blind, placebo-controlled trials investigated cyproheptadine and megestrol acetate in patients with cancer anorexia/cachexia. The first of these studies suggested that cyproheptadine could mildly stimulate appetite without causing any discernible effect on patient weight. Megestrol acetate, on the other hand, can clearly cause an increase in patient-perceived appetite and food intake and can also lead to substantial nonfluid weight gain in a proportion of patients with cancer anorexia/cachexia. Ongoing studies have been designed to better study the appetite-enhancing effects of megestrol acetate. In addition, current studies are evaluating the effect of the drug hydrazine sulfate on the appetite and weight status of patients with advanced lung or colon cancer.

AB - Anorexia and cachexia are common clinical problems of many patients with advanced cancer. Approximately 20 years ago, a controlled, clinical study demonstrated that dexamethasone could stimulate appetites of patients with advanced gastrointestinal cancer without causing any apparent effect on patient weight or survival. More recently, two double-blind, placebo-controlled trials investigated cyproheptadine and megestrol acetate in patients with cancer anorexia/cachexia. The first of these studies suggested that cyproheptadine could mildly stimulate appetite without causing any discernible effect on patient weight. Megestrol acetate, on the other hand, can clearly cause an increase in patient-perceived appetite and food intake and can also lead to substantial nonfluid weight gain in a proportion of patients with cancer anorexia/cachexia. Ongoing studies have been designed to better study the appetite-enhancing effects of megestrol acetate. In addition, current studies are evaluating the effect of the drug hydrazine sulfate on the appetite and weight status of patients with advanced lung or colon cancer.

UR - http://www.scopus.com/inward/record.url?scp=0025647080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025647080&partnerID=8YFLogxK

M3 - Article

C2 - 2259930

AN - SCOPUS:0025647080

VL - 17

SP - 8

EP - 12

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 6 SUPPL. 9

ER -